HIV Prevention and Adherence Among Priority Drug Using Populations

优先吸毒人群的艾滋病毒预防和依从性

• 批准号: 8628827
• 负责人: MICHAEL COPENHAVER
• 金额: $ 13.94万
• 依托单位: UNIVERSITY OF CONNECTICUT STORRS
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-04-01 至 2018-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8628827
• 关键词: AIDS prevention; AIDS/HIV problem; Acquired Immunodeficiency Syndrome; Adherence; Adopted; Allied Health Sciences; Anti-Retroviral Agents; Applications Grants; Area; Awareness; Behavior; Behavior Therapy; Centers for Disease Control and Prevention (U.S.); Clinical; Clinical Sciences; Collaborations; Committee Members; Communicable Diseases; Connecticut; Development; Diffusion; Drug Addiction; Drug usage; Drug user; Epidemic; Evaluation; Evidence based intervention; Funding; Future; Goals; Grant; HIV; HIV Infections; HIV risk; Health; Health Psychology; Health behavior; Human; Independent Scientist Award; Individual; Infection; Institutes; Interdisciplinary Study; International; Intervention; Life; Literature; Medicine; Mentors; Mentorship; Monitor; NCI Scholars Program; National Institute of Drug Abuse; Outcome; Persons; Pharmaceutical Preparations; Physicians; Population; Postdoctoral Fellow; Prevention approach; Preventive Intervention; Productivity; Public Health; Publications; Qualifying; Research; Research Activity; Research Personnel; Resources; Risk Behaviors; Risk Reduction; Science; Scientist; Substance abuse problem; Testing; Time; Training; Translational Research; United States National Institutes of Health; Universities; Wood material; Work; career; clinical care; college; cost effective; design; disorder prevention; evidence base; high risk; improved; intervention program; next generation; pandemic disease; pre-doctoral; programs; public health relevance; sex; symposium; treatment program; uptake

DESCRIPTION (provided by applicant): In this revised K02 career grant application, the candidate is requesting 5 years of funding to support a range of activities that will collectively improve the development of HIV prevention and adherence intervention approaches targeting drug users nationally and internationally. Through the CDC's Diffusion of Effective Behavioral Interventions (DEBI) program, a number of evidence-based HIV prevention approaches are now widely available for use with people living with HIV/AIDS (PLWA). The substantial resources required for training, implementation, monitoring, and evaluation of current EBIs targeting HIV+ DUs, however, reduces the likelihood that these EBIs can be properly adopted and sustained in common clinical settings (e.g., drug treatment programs, HIV clinical care settings, correctional settings, etc.). Moreover, the uptake of EBIs applicable to HIV+ DUs has been quite limited and the number of new annual HIV infections - a significant portion of which are directly and indirectly attributable to HIV+ DUs - has remained ~56,300 in the U.S. Thus, HIV+ DUs remain an important priority population since only HIV+ persons can transmit new infections and because DUs continue to contribute greatly to the persistent HIV epidemic via drug- and sex-related HIV risk behaviors that are entirely preventable through properly tailored and strategically placed interventions that are efficacious, cost-effective, and sustainable in clinica settings. NIDA has recognized this translational gap and has provided funding for the candidate's research team to adapt and optimize EBI approaches for implementation among priority populations in drug treatment and correctional settings. The activities proposed in this revised K02 (Independent Scientist Award) provide the essential framework and release time for the candidate to contribute to the next generation of HIV prevention and adherence programs targeting this priority population with the ultimate goal of improving the HIV pandemic.

描述（由申请人提供）：在此修订的K 02职业资助申请中，候选人要求5年的资金，以支持一系列活动，这些活动将共同改善针对国内和国际吸毒者的艾滋病毒预防和依从性干预方法的发展。通过疾病预防控制中心的有效行为干预传播（DEBI）计划，一些基于证据的艾滋病毒预防方法现在广泛用于艾滋病毒/艾滋病患者（PLWA）。然而，培训、实施、监测和评估目前针对HIV+ DU的EBI所需的大量资源降低了这些EBI在常见临床环境中被适当采用和维持的可能性（例如，药物治疗方案、HIV临床护理环境、矫正环境等）。此外，适用于HIV+ DU的EBI的吸收相当有限，并且每年新的HIV感染的数量-其中很大一部分直接和间接归因于HIV+ DU-在美国保持在~ 56，300。艾滋病毒阳性吸毒者仍然是一个重要的优先人群，因为只有艾滋病毒阳性者人可以传播新的感染，而且由于吸毒者继续通过毒品和性行为极大地助长艾滋病毒的持续流行，相关的艾滋病毒风险行为是完全可以预防的，通过适当的定制和战略性的干预措施，是有效的，成本效益高，可持续的临床环境。NIDA已经认识到这一翻译差距，并为候选人的研究团队提供资金，以适应和优化EBI方法，在药物治疗和矫正环境中的优先人群中实施。修订后的K 02（独立科学家奖）中提出的活动为候选人提供了必要的框架和发布时间，以促进针对这一优先人群的下一代艾滋病毒预防和依从性计划，最终目标是改善艾滋病毒的流行。